clinical trial · NCT05610189
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
Cerevel Therapeutics, LLC·phase1·completed·n = 25
Parkinson DiseaseTavapadon
brief summary
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
started
Dec 15, 2022
primary completion
Dec 12, 2023
completion
Dec 17, 2023
last updated
Feb 8, 2024
official title
A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol